trending Market Intelligence /marketintelligence/en/news-insights/trending/3cF6UlHr38D1yhJ4IBCuiA2 content esgSubNav
In This List

US FDA expands approval of Horizon treatment to include younger children

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


US FDA expands approval of Horizon treatment to include younger children

The U.S. Food and Drug Administration expanded the approval of Horizon Pharma Plc's Procysbi to include the treatment of children aged 1 year and above.

The drug, meant to treat a rare metabolic disorder called nephropathic cystinosis, is already approved for the treatment of adults and children as young as two years of age.

The approval was based on the results of a 17-patient study.